Literature DB >> 21570123

Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load.

Jann-Yuan Wang1, Chen-Hua Liu, Fu-Chang Hu, Hsiu-Ching Chang, Jia-Luen Liu, Jong-Min Chen, Chong-Jen Yu, Li-Na Lee, Jia-Horng Kao, Pan-Chyr Yang.   

Abstract

OBJECTIVES: Hepatitis during anti-tuberculous treatment (HATT) has been an obstacle in managing patients with tuberculosis (TB). We evaluate the risk factors of HATT and the clinical implications of serum viral loads in those with concomitant hepatitis B or C viruses (HBV/HCV) infection.
METHODS: We did a prospective study on patients with pulmonary tuberculosis in a medical center. HATT was defined as an increase in serum transaminase level of >3 times the upper limit of normal (ULN) with symptoms, or an increase in serum transaminase level of >5 times ULN without symptoms.
RESULTS: 360 TB patients were studied. The prevalence of concomitant HBV and HCV infection was 11.7% and 6.7%, respectively. HATT developed in 68 (18.9%). Cox regression analysis revealed that severe chronic kidney disease without hemodialysis, N-acetyltransferase (NAT2) slow acetylator, high initial HBV/HCV viral load, and women in those without HBV/HCV infection were significant predictors of drug-induced HATT, whereas severe chronic kidney disease without hemodialysis and men with high initial HBV/HCV viral load were significantly associated virus-induced HATT.
CONCLUSION: HBV/HCV viral load interacts with gender and, together with severe chronic kidney disease without hemodialysis and NAT2 slow acetylator, were predictors of HATT. TB patients with these characteristics need close follow-up.
Copyright © 2011 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21570123     DOI: 10.1016/j.jinf.2011.04.005

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  27 in total

1.  Anti-tuberculosis drug-induced liver injury in Shanghai: validation of Hy's Law.

Authors:  Xin Shen; Zheng'an Yuan; Jian Mei; Zurong Zhang; Juntao Guo; Zheyuan Wu; Jie Wu; Haihua Zhang; Jieping Pan; Wenming Huang; Huili Gong; Dong Yuan; Ping Xiao; Yanqin Wang; Yi Shuai; Senlin Lin; Qichao Pan; Tong Zhou; Paul B Watkins; Fan Wu
Journal:  Drug Saf       Date:  2014-01       Impact factor: 5.606

Review 2.  Hepatotoxicity from antituberculous therapy in the elderly: a systematic review.

Authors:  Jennifer D Hosford; Michael E von Fricken; Michael Lauzardo; Myron Chang; Yunfeng Dai; Jennifer A Lyon; John Shuster; Kevin P Fennelly
Journal:  Tuberculosis (Edinb)       Date:  2014-12-18       Impact factor: 3.131

Review 3.  Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.

Authors:  Vidyasagar Ramappa; Guruprasad P Aithal
Journal:  J Clin Exp Hepatol       Date:  2012-12-20

Review 4.  An Update on Drug-induced Liver Injury.

Authors:  Harshad Devarbhavi
Journal:  J Clin Exp Hepatol       Date:  2012-09-21

Review 5.  Oxidative Stress and First-Line Antituberculosis Drug-Induced Hepatotoxicity.

Authors:  Wing Wai Yew; Kwok Chiu Chang; Denise P Chan
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

6.  Baseline HBV load increases the risk of anti-tuberculous drug-induced hepatitis flares in patients with tuberculosis.

Authors:  Chun-Hui Zhu; Man-Zhi Zhao; Guang Chen; Jun-Ying Qi; Jian-Xin Song; Qin Ning; Dong Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-02-22

7.  NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis.

Authors:  M Richardson; J Kirkham; K Dwan; D J Sloan; G Davies; A L Jorgensen
Journal:  Int J Tuberc Lung Dis       Date:  2019-03-01       Impact factor: 2.373

8.  Incidence and associated risk factors of antituberculosis drug-induced hepatotoxicity among hospitalised patients in Wuhan, China.

Authors:  Na Xu; Jing Xiang Yang; Jian Yang
Journal:  Eur J Hosp Pharm       Date:  2020-09-28

9.  Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis.

Authors:  Yuag-Meng Liu; Yu-Jen Cheng; Yu-Lin Li; Chun-Eng Liu; Wu-Huei Hsu
Journal:  Lung       Date:  2013-11-30       Impact factor: 2.584

10.  Characteristics and TB treatment outcomes in TB patients with viral hepatitis, New York City, 2000-2010.

Authors:  G Bushnell; N L Stennis; A M Drobnik; D C Proops; S D Ahuja; K Bornschlegel; J Fuld
Journal:  Epidemiol Infect       Date:  2014-11-12       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.